480 related articles for article (PubMed ID: 33305478)
1. Switching between biologics in severe asthma patients. When the first choice is not proven to be the best.
Papaioannou AI; Fouka E; Papakosta D; Papiris S; Loukides S
Clin Exp Allergy; 2021 Feb; 51(2):221-227. PubMed ID: 33305478
[TBL] [Abstract][Full Text] [Related]
2. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
[TBL] [Abstract][Full Text] [Related]
3. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
[TBL] [Abstract][Full Text] [Related]
4. Role of Biologics in Asthma.
McGregor MC; Krings JG; Nair P; Castro M
Am J Respir Crit Care Med; 2019 Feb; 199(4):433-445. PubMed ID: 30525902
[TBL] [Abstract][Full Text] [Related]
5. The use of biologics in personalized asthma care.
Watchorn D; Holguin F
Expert Rev Clin Immunol; 2021 Dec; 17(12):1301-1309. PubMed ID: 34767743
[TBL] [Abstract][Full Text] [Related]
6. Biological treatments in childhood asthma.
Nieto-García A; Nieto-Cid M; Mazón-Ramos Á
Curr Opin Allergy Clin Immunol; 2024 Jun; 24(3):114-121. PubMed ID: 38567842
[TBL] [Abstract][Full Text] [Related]
7. Biologics for Severe Asthma: Treatment-Specific Effects Are Important in Choosing a Specific Agent.
Krings JG; McGregor MC; Bacharier LB; Castro M
J Allergy Clin Immunol Pract; 2019; 7(5):1379-1392. PubMed ID: 31076056
[TBL] [Abstract][Full Text] [Related]
8. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
[TBL] [Abstract][Full Text] [Related]
9. Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose?
Giovannini M; Mori F; Barni S; de Martino M; Novembre E
Ital J Pediatr; 2019 Nov; 45(1):151. PubMed ID: 31779657
[TBL] [Abstract][Full Text] [Related]
10. The potential of biologics for the treatment of asthma.
Pelaia G; Vatrella A; Maselli R
Nat Rev Drug Discov; 2012 Dec; 11(12):958-72. PubMed ID: 23197041
[TBL] [Abstract][Full Text] [Related]
11. Promises and challenges of biologics for severe asthma.
Tan R; Liew MF; Lim HF; Leung BP; Wong WSF
Biochem Pharmacol; 2020 Sep; 179():114012. PubMed ID: 32389637
[TBL] [Abstract][Full Text] [Related]
12. Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study.
Menzella F; Galeone C; Ruggiero P; Bagnasco D; Catellani C; Facciolongo N
Pulm Pharmacol Ther; 2020 Feb; 60():101874. PubMed ID: 31857207
[TBL] [Abstract][Full Text] [Related]
13. Severe asthma: When to resort to biological agents.
Tenero L; Rossignoli S; Piacentini G
Pediatr Allergy Immunol; 2020 Feb; 31 Suppl 24():37-39. PubMed ID: 32017206
[TBL] [Abstract][Full Text] [Related]
14. Biologics for oral corticosteroid-dependent asthma.
Yılmaz İ
Allergy Asthma Proc; 2020 May; 41(3):151-157. PubMed ID: 32375958
[No Abstract] [Full Text] [Related]
15. The clinical profile of benralizumab in the management of severe eosinophilic asthma.
Menzella F; Lusuardi M; Galeone C; Facciolongo N; Zucchi L
Ther Adv Respir Dis; 2016 Dec; 10(6):534-548. PubMed ID: 27612492
[TBL] [Abstract][Full Text] [Related]
16. [SWITCHING BIOLOGICS LED TO GOOD CONTROL IN SEVERE CHILDHOOD ASTHMA: A CASE REPORT].
Imai A; Takizawa T; Sato K; Inoue T; Nishida Y; Yagi H; Arakawa H
Arerugi; 2019; 68(7):869-873. PubMed ID: 31406083
[TBL] [Abstract][Full Text] [Related]
17. Biologics for paediatric severe asthma: trick or TREAT?
Saglani S; Bush A; Carroll W; Cunningham S; Fleming L; Gaillard E; Gupta A; Murray C; Nagakumar P; Paton J; Roberts G; Seddon P; Sinha I
Lancet Respir Med; 2019 Apr; 7(4):294-296. PubMed ID: 30824361
[No Abstract] [Full Text] [Related]
18. Biological therapy management from the initial selection of biologics to switching between biologics in severe asthma.
Yılmaz İ; Paçacı Çetin G; Arslan B; Şeker S; Bozkurt Yılmaz HE; Aktaş Yapıcı E; Köylüce S; Açar E
Tuberk Toraks; 2023 Mar; 71(1):75-93. PubMed ID: 36912412
[TBL] [Abstract][Full Text] [Related]
19. Home Self-Administration of Biologics - A German Survey among Omalizumab-Treated Patients with Severe Asthma and their Treating Physicians.
Timmermann H; Mailänder C
Pneumologie; 2020 Feb; 74(2):103-111. PubMed ID: 31935761
[TBL] [Abstract][Full Text] [Related]
20. Pediatric asthma: guidelines-based care, omalizumab, and other potential biologic agents.
Huffaker MF; Phipatanakul W
Immunol Allergy Clin North Am; 2015 Feb; 35(1):129-44. PubMed ID: 25459581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
